Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This clinical trial aims to compare the efficacy and safety of applying "PeptiCol EZgraft" in extraction socket preservation procedures against "Regenomer," in terms of reducing the amount of alveolar bone change during the healing process following tooth extraction.
Full description
The purpose of this clinical trial is to compare the efficacy and safety of using "PeptiCol EZgraft" in extraction socket preservation procedures against "Regenomer," specifically to evaluate whether PeptiCol EZgraft is more effective in reducing alveolar bone changes compared to Regenomer. The trial aims to assess both the effectiveness and safety of PeptiCol EZgraft in minimizing alveolar bone resorption during the healing process following tooth extraction.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Extensive alveolar bone absorption observed in the extraction socket area.
Severe periodontal disease or acute periodontal abscess.
Poor oral hygiene.
History of bone grafts or implants in the area of the medical device application.
Mucosal diseases due to autoimmune disorders.
History of hypersensitivity to collagen preparations.
Smoking more than 10 cigarettes per day.
Alcohol or drug addiction.
*The alcohol addiction screening will be conducted using AUDIT-K.
Use of drugs affecting bone formation within 2 weeks prior to screening (e.g., steroids, bisphosphonates).
Use of oral or injectable rheumatic medications, including immunosuppressants, within 2 weeks prior to screening.
History of or current use of oral or injectable bisphosphonates for osteoporosis for more than 12 weeks.
Uncontrolled bleeding disorders or use of medications affecting blood coagulation.
Uncontrolled diabetes or hypertension.
Clinically significant cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous system diseases observed at screening.
Immune disorders including acquired immunodeficiency syndrome.
Pregnant or breastfeeding women
During the clinical trial period, female and male participants who are of childbearing potential must agree to use appropriate contraception from the date of signing the informed consent form until the end of the clinical trial (16 weeks post-procedure). If a female participant becomes pregnant during the trial period, her participation will be discontinued.
Primary purpose
Allocation
Interventional model
Masking
114 participants in 2 patient groups
Loading...
Central trial contact
Park Shin young
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal